key: cord-0927838-vufks9oq
authors: Armeni, Eleni; Paschou, Stavroula A.; Peppa, Melpomeni
title: Managing diabetes in ageing patients during the COVID-19 pandemic
date: 2020-11-17
journal: Maturitas
DOI: 10.1016/j.maturitas.2020.11.002
sha: 3a6f14e1e83e25c33fb1ab18dcf4eb82265bece8
doc_id: 927838
cord_uid: vufks9oq

nan

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

(ACE-2) receptor, and insulin deficiency or an indirect effect through systemic inflammation and/or metabolic changes in other organs such as liver, muscle or adipose tissue, leading to insulin resistance [5] . Age seems to be an important factor related to COVID-19 mortality and this association seems to be largely mediated by the presence of DM [1] . Patients with DM, and especially those not adequately controlled, are prone to critical COVID-19 condition with a bad response to treatment [6, 7] .

Although there is a lot more to learn about the COVID-19 pandemic, what we have already understood is that patients with DM constitute a group with severe adverse outcomes, emphasizing the need for optimal glycemic control [8] . This task might be particularly challenging for the ageing population, as these patients are not used to virtual consultations provided by telemedicine, while they present other comorbidities that need face-to-face evaluation [9] . HbA1c levels should be evaluated as an indicator of glycemic control, aiming for a general target <7% or a higher individualized goal, depending on the comorbidities, without hypoglycemia. Physicians should remind patients the importance of lifestyle measures, such as a healthy diet, adequate hydration and regular physical activity. They should also be encouraged to measure capillary blood glucose and assess ketones, especially when they feel unwell and follow the sick day rules [8] .

Specific attention should be paid in the re-evaluation of the anti-diabetic treatment in the context of the COVID-19 pandemic. Although metformin is the gold standard first choice of treatment in DM, it has to be withheld as soon as suspicious symptoms arise, aiming to minimize the risk of lactic acidosis.

Sodium-glucose transport inhibitors (SGLT-2i) precipitate towards a reverse insulin/glucagon ratio, and thus higher rates of ketosis, likely to complicate clinical manifestations of COVID-19 infection [10] ; therefore their administration should be kept to a minimum. Treatment with glucagon like peptide 1 receptor agonists (GLP-1RA), a safe and effective anti-diabetic option in general, has been associated with an upregulation of ACE-2 inhibitors, which implies a possible adverse effect on the severity of immune reaction related with the disease [10] . Thiazolidinediones (TZDs) regulate not only glucose levels but also immune system response, through activation of the peroxisome proliferator activated J o u r n a l P r e -p r o o f receptor-γ (PPARγ) [11] . However, initiation of TZDs to control the exaggerated catecholamine response during the early stages of suspected COVID-19 infection should be rather avoided; more studies are needed regarding their efficacy in this specific situation. Sulfonylureas are less commonly used nowadays due to the risk of hypoglycemia and their short durability of action. Such a treatment should be readjusted after a confirmed infection, due to the possible viral damage on pancreatic islet cells and possible insulin deficiency observed in patients with COVID-19 [4, 5] . Dipeptidyl peptidase 4 inhibitors (DPP-4i) might have a potential positive effect in regulation of the infectious process [10] , so the use of these agents appears as a rather efficient and safe choice.

In-person follow-up appointments and re-evaluation of anti-diabetic treatment are especially indicated for older patients who have managed to overcome the respiratory failure linked with the infection and have been discharged with oral steroids, which can aggravate hyperglycemia [12, 13] . DM is not only a risk factor for COVID-19, but it can also be complicated by severe and potentially life-threatening emergencies. Health care practitioners should be aware of the relationship of DM with COVID-19 infection and its adverse outcome. It is of high priority to make also patients aware of this association and to educate them to control hyperglycemia effectively and as soon as possible. This is even more necessary in ageing patients with DM and can be achieved by maintaining an ongoing physicianpatient interaction, and by willingness to readjust DM regimens based on available data and growing new evidence.

Eleni Armeni wrote the initial draft. 

The effects of aging on host resistance and disease tolerance to SARS-CoV-2 infection

The Novel Coronavirus Disease (COVID-19): A PRISMA Systematic Review and Meta-Analysis of Clinical and Paraclinical Characteristics

Diabetes and COVID-19: Global and regional perspectives

Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

The association of diabetes and the prognosis of COVID-19 patients: a retrospective study

Characteristics and outcomes of the hyperglycemic hyperosmolar non-ketotic syndrome in a cohort of 51 consecutive cases at a single center

COVID-19 in people living with diabetes: An international consensus

The Effects of COVID-19 on Telemedicine Could Outlive the Virus

Diabetes and Novel Coronavirus Infection: Implications for Treatment

Pharmacological (or synthetic) and nutritional agonists of PPAR-γ as candidates for cytokine storm modulation in covid-19 disease 2020

EMA starts review of dexamethasone for treating adults with COVID-19 requiring respiratory support | European Medicines Agency

Covid-19: The inside story of the RECOVERY trial

The authors declare that they have no conflict of interest.

No funding was received for the preparation of this editorial.

This article was commissioned and was not externally peer reviewed.J o u r n a l P r e -p r o o f